- Ten Hag bemoans Man Utd's lack of killer instinct in Palace stalemate
- France's Macron appoints new government in shift to right
- Cheika proud of Leicester grit after winning start as boss
- Profligate Man Utd pay price in 0-0 draw at Palace
- Kane, Olise run riot as Bayern thump Bremen
- Diaz fires Liverpool top of Premier League, Man Utd held at Palace
- LIV champion Rahm out of LIV Team semis with severe flu
- Slot surprised by tearful Nunez's moment of magic
- Title rivals Norris, Verstappen on 'cool' front row for Singapore GP
- Biden talks China with 'Quad' leaders in hometown summit
- Juve and Napoli play out goalless draw in early Serie A title tussle
- Alcaraz fears tennis tour grind will 'kill us'
- Carey sparks recovery as Australia thrash England in 2nd ODI
- Leclerc, Sainz lament 'disappointing' Saturday in Singapore
- Bottega Veneta holds investors' aces as Madonna pops into D&G
- Beirut digs for victims at building flattened in Israeli strike
- Verstappen stages protest over 'ridiculous' swearing punishment
- Bayern boss Kompany lauds 'special talent' Olise
- Diaz fires Liverpool top of Premier League, Spurs bounce back
- Heavy fire over Israel-Lebanon border after deadly Beirut strike
- Ramos guides unbeaten Toulouse to Montpellier win despite Hogg scuffle
- Myanmar flood death toll jumps to 384
- Chelsea owners 'happy' with win at West Ham amid rift report
- Kane and Olise run riot as Bayern thump Bremen
- Ramos guides unbeaten Toulouse to Montpellier win
- Norris pips Verstappen to dramatic Singapore pole after Sainz crash
- Carey takes Australia to 270 in 2nd ODI against England after collapse
- Two Hezbollah leaders killed in Israel's Beirut strike
- Hungary Danube waters reach decade high after Storm Boris
- Bagnaia cuts Martin's MotoGP lead with Emilia-Romagna sprint win
- Jackson double fires Chelsea to victory at woeful West Ham
- Fiji beat Japan to lift Pacific Nations Cup
- Kasatkina to face Haddad Maia in Korea Open final
- S.Africa snowfall closes roads, strands motorists overnight
- Lawyers of women alleging Al-Fayed sex abuse receive over 150 new enquiries
- President Museveni's son backs Ugandan strongman for 7th term
- Norris quickest as Verstappen bounces back in Singapore practice
- Wallabies lament All Blacks' fast start
- Germany's Oktoberfest opens under tight security after attacks
- Environmental protesters block French cruise liner port
- Hezbollah in disarray after Israeli strike kills top commanders
- No place like home: Biden hosts 'Quad' leaders
- One dead, 7 missing as heavy rains trigger floods in central Japan
- Zelensky says no UK, US go-ahead to use long-range missiles
- New Zealand edge Australia 31-28 in Bledisloe Cup thriller
- Japan orders evacuations as heavy rains trigger floods in quake-hit area
- New Zealand pilot freed in Indonesia after 19 months in rebel captivity
- Hezbollah in disarray after Israeli air strike kills top commanders
- The BYD Seal Hybrid U DM-i AWD in a practical test by journalists
- Leading climate activist released from Vietnam jail
Every month counts: European ALS patients want new drugs
Olivier Goy is running out of time.
The French entrepreneur was diagnosed in 2020 with amyotrophic lateral sclerosis (ALS) -- the incurable neurodegenerative disease that normally claims the lives of patients within three to five years.
There are new treatments that have given patients hope of being able to extend their lives by an invaluable few months, but the approval process in Europe is taking time, infuriating desperate patients.
"When you are certain to die soon, patients and some doctors are ready to take some risks," Goy told AFP.
In response to the lack of new treatments in his native France, the founder of the fintech start-up October spends 3,000 euros ($3,180) every month to buy the ingredients to make his own drugs.
ALS, also known as Lou Gehrig's disease, attacks the motor nerve cells in the brain and spinal cord, progressively paralysing muscles until patients cannot walk, eat, speak or breathe.
Around one in 10,000 people have the disease in the EU, according to the European Medicines Agency.
The drug Riluzole, which has been available in Europe and the UK since the 1990s, is capable of prolonging the lives of patients by around three months.
But otherwise, no new treatment has been approved in Europe for more than two decades.
- 'First hope in 20 years' -
A new treatment called AMX0035 was given the green light in the United States and Canada last year.
"It is the first hope we have had in 20 years: the first drug which is aimed at everyone and which had results" suggesting up to six months in added life expectancy, said Sabine Turgeman, head of the French Association for Research into ALS.
But the extent of the benefits of AMX0035 remains unclear. The US Food and Drug Administration approved the drug, sold under the name Relyvrio, based on the results of a single Phase 2 trial that involved just 137 participants.
The drug's developer, Amylyx Pharmaceuticals, is conducting larger, more comprehensive trials, with results expected in 2024.
Amylyx said earlier this month that the European Union's drug watchdog EMA is reviewing its submission for approval and it expects a decision in the first half of this year.
But for those with the disease, every delay represents a significant amount of the time they have left.
"It's not going fast enough," Turgeman said. "This disease is not on bureaucratic time".
For European patients who cannot afford to import their own ingredients like Goy, the only way to get access to new treatments is to join a clinical trial.
But such trials have very specific criteria for selection -- and even if a patient gets in, there is a chance they will be in the group given a placebo.
- 'Totally abandoned' -
Given how swiftly the disease progresses, patients and families are pressing for more options.
"We feel totally abandoned," said Sophie Garofalo, whose brother was diagnosed with ALS five years ago.
His family tried to enter him into clinical trials, "but either he does not meet the criteria, or the trials have already started," she said.
"He is ready to take anything, try everything".
French pharmaceutical company AB Science is developing another potential treatment using the drug masitinib, which initial results suggest could add months to the lives of patients.
The firm's CEO Alain Moussy said that because "time is very limited" for ALS patients, there should be more flexibility in the approval system.
"What degree of risk should be taken? That's for the health agencies to answer -- but they can guided by policymakers and patients," he said.
O.M.Souza--AMWN